Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: A systematic review

Evidence-Based Medicine

Volumn 22, Issue 5, 2017, Pages 170-177

  Hadi, Muhammad Abdul ^a   Mchugh, Gretl A ^b   Conaghan, Philip G ^c,d  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Chapel Allerton Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADVERSE EVENT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DRUG SAFETY; EARLY INTERVENTION; GENERAL PRACTICE; HARM REPORTING SCORING SYSTEM; HEALTH CARE QUALITY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PATIENT HARM; PHARMACEUTICAL CARE; PROTOCOL COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SAMPLE SIZE; SCORING SYSTEM; SYSTEMATIC REVIEW; THERAPEUTIC INDEX; TREATMENT INDICATION;

EID: 85030647289     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed-2017-110715     Document Type: Article

References (18)

1. Seruga B, Templeton AJ, Badillo FE, et al. Under-reporting of harm in clinical trials. Lancet Oncol 2016; 17: e209-19.
2. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781-8.
3. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ 1996; 313: 570-1.
4. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94.
5. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials?. A systematic review. Med J Aust 2006; 185: 263-7.
6. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol 2007; 60: 241-9.
7. Devereaux PJ, Manns BJ, Ghali WA, et al. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials 2002; 23: 380-8.
8. Han C, Kwak KP, Marks DM, et al. The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. Contemp Clin Trials 2009; 30: 116-22.
9. Péron J, Maillet D, Gan HK, et al. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol 2013; 31: 3957-63.
10. Smith SM, Chang RD, Pereira A, et al. Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. Pain 2012; 153: 2415-21.
11. Hodkinson A, Kirkham JJ, Tudur-Smith C, et al. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open 2013; 3: e003436.
12. Carmichael K, Nolan SJ, Weston J, et al. Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria. Epilepsy Res 2015; 114: 106-13.
13. Turner LA, Singh K, Garritty C, et al. An evaluation of the completeness of safety reporting in reports of complementary and alternative medicine trials. BMC Complement Altern Med 2011; 11: 67.
14. Pitrou I, Boutron I, Ahmad N, et al. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169: 1756-61.
15. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 2004; 22: 19-22.
16. Ethgen M, Boutron I, Baron G, et al. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med 2005; 143: 20-5.
17. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006; 24: 3933-8.
18. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-32.